# Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

> **NCT04745832** · PHASE3 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 82 (actual)

## Conditions studied

- Follicular Lymphoma (FL)
- Non Hodgkin Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Zandelisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT04745832
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-13
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 82 (ACTUAL)
- **Why stopped:** Discontinuation of zandelisib program
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745832, "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04745832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*